Search
Now showing items 1-5 of 5
A HUWE1 defect causes PARP inhibitor resistance by modulating the BRCA1-∆11q splice variant.
(SPRINGERNATURE, 2023-09-01)
Although PARP inhibitors (PARPi) now form part of the standard-of-care for the treatment of homologous recombination defective cancers, de novo and acquired resistance limits their overall effectiveness. Previously, ...
Mechanism of assembly, activation and lysine selection by the SIN3B histone deacetylase complex.
(NATURE PORTFOLIO, 2023-05-03)
Lysine acetylation in histone tails is a key post-translational modification that controls transcription activation. Histone deacetylase complexes remove histone acetylation, thereby repressing transcription and regulating ...
The proteomic landscape of soft tissue sarcomas.
(NATURE PORTFOLIO, 2023-06-29)
Soft tissue sarcomas (STS) are rare and diverse mesenchymal cancers with limited treatment options. Here we undertake comprehensive proteomic profiling of tumour specimens from 321 STS patients representing 11 histological ...
Characterization of proteome-size scaling by integrative omics reveals mechanisms of proliferation control in cancer.
(AMER ASSOC ADVANCEMENT SCIENCE, 2023-01-25)
Almost all living cells maintain size uniformity through successive divisions. Proteins that over and underscale with size can act as rheostats, which regulate cell cycle progression. Using a multiomic strategy, we leveraged ...
Cancer-associated FBXW7 loss is synthetic lethal with pharmacological targeting of CDC7.
(WILEY, 2023-10-22)
The F-box and WD repeat domain containing 7 (FBXW7) tumour suppressor gene encodes a substrate-recognition subunit of Skp, cullin, F-box (SCF)-containing complexes. The tumour-suppressive role of FBXW7 is ascribed to its ...